442 related articles for article (PubMed ID: 12640150)
1. Clinical role of FDG PET in evaluation of cancer patients.
Kostakoglu L; Agress H; Goldsmith SJ
Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
3. PET imaging in breast cancer.
Bombardieri E; Crippa F
Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
[TBL] [Abstract][Full Text] [Related]
4. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
6. Oncological applications of FDG PET imaging.
Delbeke D
J Nucl Med; 1999 Oct; 40(10):1706-15. PubMed ID: 10520713
[No Abstract] [Full Text] [Related]
7. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose-PET in the management of breast cancer.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
[TBL] [Abstract][Full Text] [Related]
10. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
11. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
12. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
14. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET.
Reinhardt MJ; Ehritt-Braun C; Vogelgesang D; Ihling C; Högerle S; Mix M; Moser E; Krause TM
Radiology; 2001 Mar; 218(3):776-82. PubMed ID: 11230656
[TBL] [Abstract][Full Text] [Related]
15. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
16. [The role of diagnostic PET in treatment planning before tumor surgery].
Haberkorn U
Chirurg; 2001 Sep; 72(9):1010-9. PubMed ID: 11594269
[TBL] [Abstract][Full Text] [Related]
17. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
18. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
20. Thoracic FDG PET: state of the art.
Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]